SubHero Banner

Blenrep ® (belantamab mafodotin-blmf) – New orphan drug approval

August 6, 2020 - GlaxoSmithKline announced the FDA approval of Blenrep (belantamab mafodotin-blmf), for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Download PDF